TransThera Unveils Promising Tinengotinib Research Against Cholangiocarcinoma

TransThera Unveils Promising Tinengotinib Research Against Cholangiocarcinoma



TransThera Sciences Inc. has made significant strides in the fight against cholangiocarcinoma (CCA) with the publication of their latest translational studies featuring tinengotinib (TT-00420) in the renowned Annals of Oncology, which boasts an impressive impact factor of 56.7. This remarkable research has been led by Dr. Peng Peng, the Vice President at TransThera, who has served as a co-first author on the publication.

Cholangiocarcinoma, a malignant cancer that affects the bile ducts, is known for its aggressive nature and is often spurred by mutations in the FGFR2 gene. These mutations typically arise from the inhibitors previously used, such as pemigatinib and futibatinib; however, patients frequently develop resistance as the cancer evolves. This new paper exemplifies a comprehensive approach, integrating various analyses to model the biology behind the acquired resistance and to pave the way for future FGFR inhibitors.

Among the standout findings of this study is the initial revelation of the co-crystal structure of tinengotinib with the active FGFR2 kinase domain, showcasing its unique binding affinity. The research highlights not only the structural aspects but also kinetic studies that underline tinengotinib's superior affinity relative to existing first-generation FGFR inhibitors. This is complemented by findings highlighting its effectiveness against clinically acquired FGFR2 resistance mutations, both in vitro and in vivo, alongside a notable case report that demonstrates its therapeutic efficacy.

Dr. Lipika Goyal, the Director of Gastrointestinal Oncology at the Stanford Cancer Center and principal investigator, emphasized the importance of the study's extensive dataset, which utilized nearly 500 clinical samples to analyze resistance. Her insights reflect on the collaborative effort required to tackle rare and challenging cancers like CCA, stating, "This study will be a substantial contribution to the field that will advance our understanding of acquired resistance to FGFR inhibitors."

Furthermore, Dr. Peng expressed enthusiasm regarding the implications of their findings: "We are delighted that TransThera's discovery is a critical element in the fundamental research aimed at overcoming FGFR refractory cases. Our ongoing phase 3 clinical trials will serve to validate our approach in delivering a novel treatment option for CCA patients."

Understanding Tinengotinib
Tinengotinib is a globally recognized multi-kinase inhibitor designed to combat tumors by targeting not just FGFRs, but also VEGFRs, Aurora A/B, and Janus kinases (JAK). Current clinical trials underway in both the United States and China are investigating its efficacy across a variety of solid tumors, and it has already obtained Orphan Drug Designation and Fast Track Designation from the FDA, alongside Breakthrough Therapy Designation from China's NMPA.

About TransThera
TransThera Sciences is a clinical-stage biopharmaceutical company committed to creating innovative small molecule therapies, particularly focused on oncology and inflammatory diseases. With a strategic approach to drug development, TransThera aims to fulfill urgent clinical needs worldwide through the development of first-in-class or best-in-class drugs. For further details, visit www.transthera.com.

Conclusion
The release of these findings marks a pivotal moment in the research of cholangiocarcinoma and the broader landscape of cancer therapeutics. As TransThera continues its mission, the medical community remains optimistic about the potential advancements brought forth by tinengotinib and its role in overcoming resistance in targeted cancer therapies.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.